Los Angeles, CA, United States of America

Jeffrey Lance Creech

This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Zoll Circulation, Incorporated. Active years: 2026.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Jeffrey Lance Creech

Introduction

Jeffrey Lance Creech is an accomplished inventor based in Los Angeles, CA. He has made significant contributions to the field of medical technology, particularly in oxygen-enrichment therapy. His innovative approach focuses on enhancing patient care through advanced monitoring techniques.

Latest Patents

Creech holds a patent for a "System and method for controlling oxygen-enrichment therapy based on microvascular resistance feedback." This patent outlines systems and methods for controlling gas-enrichment therapy, utilizing sensors and imaging systems to measure physiological parameters of patients. The feedback provided by these systems is crucial for titrating or controlling gas-enrichment therapy effectively.

Career Highlights

Creech is currently employed at Zoll Circulation, Incorporated, where he continues to develop and refine technologies that improve patient outcomes. His work is characterized by a commitment to innovation and excellence in the medical field.

Collaborations

Creech has collaborated with notable colleagues, including Stephen Elwood Myrick and Richard A Helkowski. These partnerships have fostered a collaborative environment that enhances the development of cutting-edge medical technologies.

Conclusion

Jeffrey Lance Creech's contributions to medical technology, particularly in oxygen-enrichment therapy, demonstrate his dedication to improving patient care through innovation. His work continues to influence the field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…